PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31507426-10 2019 In all the patients, including patients who received both pemetrexed and platinum, SNP rs1801133 on the MTHFR gene (665C > T) was found to be significantly associated with hematological ADRs in 1 to 2 cycles (P = 0.0079, OR = 3.566). Platinum 73-81 methylenetetrahydrofolate reductase Homo sapiens 104-109 32257953-8 2019 MTHFR rs1801131 and MDM2 rs1690924 were significantly correlated with platinum-induced GI toxicity (P = 0.04 and P = 0.02, respectively). Platinum 70-78 methylenetetrahydrofolate reductase Homo sapiens 0-5 29662106-3 2019 ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy. Platinum 137-145 methylenetetrahydrofolate reductase Homo sapiens 27-32 29861877-5 2018 Contrasting results, however, have been reported on the capability of variants of other genes as MTHFR, TYMS, ERCC1, XRCC1, GSTP1, CYP3A4/3A5 and ABCB1, in predicting either therapy efficacy or toxicity in patients undergoing treatment with pyrimidine antimetabolites, platinum derivatives, irinotecan and taxanes. Platinum 269-277 methylenetetrahydrofolate reductase Homo sapiens 97-102 25104092-0 2014 Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Platinum 166-174 methylenetetrahydrofolate reductase Homo sapiens 26-61 25246386-0 2014 Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Platinum 80-88 methylenetetrahydrofolate reductase Homo sapiens 24-29 25028118-0 2014 Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. Platinum 79-87 methylenetetrahydrofolate reductase Homo sapiens 21-26 25104092-8 2014 The results indicate that a heterozygous advantage may exist in certain MTHFR variants, and the polymorphisms (especially rs1537514) may play a predictive role of treatment efficacy and adverse effects in NSCLC patients treated with platinum-based chemotherapy. Platinum 233-241 methylenetetrahydrofolate reductase Homo sapiens 72-77 23463763-8 2013 CONCLUSIONS: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum. Platinum 172-180 methylenetetrahydrofolate reductase Homo sapiens 43-48 24142642-0 2013 Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis. Platinum 124-132 methylenetetrahydrofolate reductase Homo sapiens 13-48 24142642-1 2013 PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Platinum 109-117 methylenetetrahydrofolate reductase Homo sapiens 9-44 24142642-1 2013 PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Platinum 109-117 methylenetetrahydrofolate reductase Homo sapiens 46-51 24142642-3 2013 We performed meta-analysis to investigate the effect of MTHFR C677T polymorphism on lung cancer risk and response to platinum-based chemotherapy in advanced NSCLC. Platinum 117-125 methylenetetrahydrofolate reductase Homo sapiens 56-61 24142642-11 2013 In addition, MTHFR 677TT homozygote carriers had a better response to platinum-based chemotherapy in advanced NSCLC in the recessive model. Platinum 70-78 methylenetetrahydrofolate reductase Homo sapiens 13-18 24142642-12 2013 CONCLUSION: The MTHFR C677T polymorphism might be a genetic marker for lung cancer risk or response to platinum- based chemotherapy in advanced NSCLC. Platinum 103-111 methylenetetrahydrofolate reductase Homo sapiens 16-21 21605004-5 2011 In addition, we found that patients with the MTHFR 677 TT genotype showed a better response to platinum-based chemotherapy in the recessive model (TT vs CT + CC adjusted OR: 0.24; 95% CI: 0.09-0.68; p = 0.007), the generalized OR was 0.44 (0.22-0.88; p = 0.04). Platinum 95-103 methylenetetrahydrofolate reductase Homo sapiens 45-50 23020798-0 2012 Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. Platinum 109-117 methylenetetrahydrofolate reductase Homo sapiens 37-42 23020798-9 2012 CONCLUSION: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC patients treated with platinum/5-Fu-based chemotherapy. Platinum 130-138 methylenetetrahydrofolate reductase Homo sapiens 49-54 21605004-7 2011 Our results suggest that genetic polymorphisms of MTHFR 677 C T may contribute to NSCLC development in Chinese women and could also influence treatment response for advanced NSCLC patients with platinum-based chemotherapy. Platinum 194-202 methylenetetrahydrofolate reductase Homo sapiens 50-55 21182814-3 2006 The aim of this study is to investigate the relationship between genetic polymorphisms of MTHFR C677T or A1298C and the response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Platinum 132-140 methylenetetrahydrofolate reductase Homo sapiens 90-95 21182814-11 2006 CONCLUSIONS: The results suggest that the synergic effect between MTHFR C677T and A1298C polymorphisms is associated with clinical response to platinum-based chemotherapy. Platinum 143-151 methylenetetrahydrofolate reductase Homo sapiens 66-71 21182814-12 2006 Detection of MTHFR genotypes may indicate the sensitivity of NSCLC patients to platinum-based chemotherapy. Platinum 79-87 methylenetetrahydrofolate reductase Homo sapiens 13-18 16243820-4 2005 RNA expression levels of 5-FU metabolism-associated genes thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase, MAP7, and ELF3, of platinum- and taxane-related genes caldesmon, ERCC1, ERCC4, HER-2/neu, and GADD45, and of multidrug resistance gene MRP1 were determined using real-time reverse transcriptase-PCR. Platinum 194-202 methylenetetrahydrofolate reductase Homo sapiens 138-173 34730065-7 2021 MTHFR polymorphism might impact the development of pemetrexed and platinum-related toxicities but not as a clinical predictor of efficiency. Platinum 66-74 methylenetetrahydrofolate reductase Homo sapiens 0-5 34680361-13 2021 Results indicate that dietary zinc, B12 and B6 intakes may be associated with platinum sensitivity dependent on MTHFR genotype. Platinum 78-86 methylenetetrahydrofolate reductase Homo sapiens 112-117